ASHFORDINTELEvery call below was generated by our automated pipeline analyzing publicly available SEC filings. No hindsight. No cherry-picking. Dates are filing analysis dates from our system.
Accounts receivable contraction and receivables stress detected in the periodic filing.
On February 9, 2026, 255 days later, the company disclosed delayed filings, management changes, and an accounting review over internal control weaknesses. Shares plunged 53% that day.
Severe divergence between accounts receivable growth and revenue trajectory, with revenue declining 40% while AR grew 18%.
On February 3, 2026, 90 days later, the company issued 2026 sales and profit guidance below Wall Street expectations citing patent-loss pressure.
Accounts receivable growing 5.14x faster than revenue combined with discretionary accounting adjustments boosting reported earnings.
On February 10, 2026, 95 days later, the company guided 2026 outlook to the low end of expectations.
Contract losses and production claims inconsistent with disclosed capability, plus execution weakness across multiple programs.
Continued production quality concerns and execution deterioration drove sustained stock pressure through Q1 2026.
Subscription base decay and turnaround narrative tension between management claims and financial trajectory.
Shares dropped 25% that session after a revenue miss, weak guidance, and CFO departure. Stock declined 28% that month.
Operating cash flow collapse from $3.2B to $1.2B, DSO jump, and accounts receivable growing 13.8% on 0.1% revenue growth.
Shares fell 9–15% on the earnings miss, hit multi-year lows, and analyst downgrades followed.
Medical care ratio deterioration from 85.2% to 89.9%, pricing trailing costs, and the first revenue decline signal in decades.
The stock continued declining approximately 16% from filing date to 52-week lows as the MCR deterioration our system identified kept compounding. Shares were down more than 46% from the 52-week high.
Inventory growth of 41%, delivery decline, and R2 production claims inconsistent with manufacturing readiness.
Delivery pressure continued, U.S. sales declined 26% year over year, and the stock fell 24% year to date.
Litigation reserve reversal distorting reported earnings quality.
Talc litigation overhang persisted and legal uncertainty remained unresolved.